Study of torsades de pointes ventricular tachycardia in agitated delirium: a case report

1. Etchegoyen CV, Keller GA, Mrad S, et al. Drug-induced QT Interval Prolongation in the Intensive Care Unit. Clin Pharmacol. 2017;12(4):210-22. doi:10.2174/1574884713666180223123947.

2. Tsuji Y, Yamazaki M, Shimojo M, et al. Mechanisms of torsades de pointes: an update. Front Cardiovasc Med. 2024;11:1363848. doi:10.3389/fcvm.2024.1363848.

3. Kahlon SS, Sikandar R, Tejovath S, et al. Diagnosing Torsades De Pointes Based on Correlation to QT Interval: A Systematic Review. Cureus. 2022;14(8):e27833. doi:10.7759/cureus.27833

4. Aripova NR, Abdullaeva AA, Zlobina PD, et al. Pathogenesis, predictors, and prognostic scales for assessing the risk of atrial fibrillation recurrence after catheter-based treatments: a literature review. The Siberian Journal of Clinical and Experimental Medicine. 2023; 38:55-60 (In Russ.) doi:10.29001/2073-8552-2023-38-4-55-60.

5. Fujii Y, Itoh H, Ohno S, et al. A type 2 ryanodine receptor variant associated with reduced Ca2+ release and short-coupled torsades de pointes ventricular arrhythmia. Heart Rhythm. 2017;14(1):98-107. doi:10.1016/j.hrthm.2016.10.015.

6. Springer B. Hyperactive Delirium with Severe Agitation. Emerg Med Clin North Am. 2024;42(1):41-52. doi:10.1016/j.emc.2023.06.011.

7. Kiryuhina SV, Osipova VA, Kolmykov VA, et al. Features of the pathogenetic mechanisms, clinical picture, treatment, and prevention of delirium disorders associated with COVID-19. Journal of new medical technologies, eedition. 2022;16(5):29-38. (In Russ.) doi:10.24412/2075-4094-2022-5-1-4.

8. Kiryuhina SV, Zhdanova YaV, Borisova AD, et al. Some Pathogenetic Mechanisms of the Development of Mental Disorders in Patients with Cardiovascular Pathology. Medicine and Biotechnology. 2025;1(2):140-53. (In Russ.) doi:10.15507/3034-6231.001.202502.140-153.

9. Stollings JL, Kotfis K, Chanques G, et al. Delirium in critical illness: clinical manifestations, outcomes, and management. Intensive Care Med. 2021;47(10):1089-103. doi:10.1007/s00134-021-06503-1.

10. Ostroumova O.D., Goloborodova I.V. The effect of certain groups of medications on the risk of prolongation of the QT interval. Consilium Medicum. 2019;21(10):95-106. (In Russ.) doi:10.26442/20751753.2019.10.190447.

11. Ng KT, Shubash CJ, Chong JS. The effect of dexmedetomidine on delirium and agitation in patients in intensive care: systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(3):380-92. doi:10.1111/anae.14472.

12. Nikiforov II, Rakitin MM, Merkin AG, et al. Neurology, Neuropsychiatry, Psychosomatics Neurological Complications of Alcoholism. Russ J Cardiol. 2017;9:95-100. (In Russ.) doi:10.14412/2074-2711-2017-4-95-100.